Antiepileptic drug therapy: Does mechanism of action matter?

Epilepsy and Behavior

Volumn 21, Issue 4, 2011, Pages 331-341

  Brodie, Martin J ^a   Covanis, Athanasios ^b   Gil Nagel, Antonio ^c   Lerche, Holger ^d   Perucca, Emilio ^e,f   Sills, Graeme J ^g   White, H Steve ^h  

^a WESTERN INFIRMARY   (United Kingdom)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^c HOSPITAL RUBER INTERNACIONAL   (Spain)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF PAVIA   (Italy)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

Antiepileptic drugs; Antiepileptogenesis; Disease modification; Epilepsy; Epileptogenesis; Interactions; Mechanism of action; Pharmacodynamics; Pharmacokinetics; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KV7.2; POTASSIUM CHANNEL KV7.3; POTASSIUM CHANNEL STIMULATING AGENT; PREGABALIN; RETIGABINE; RUFINAMIDE; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; ACUTE PANCREATITIS; ANHIDROSIS; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; BEHAVIOR DISORDER; BENIGN CHILDHOOD EPILEPSY; CHILDHOOD ABSENCE EPILEPSY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GENE MUTATION; GENERALIZED EPILEPSY; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; LETHARGY; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NERVE CELL EXCITABILITY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; ORGANIC BRAIN SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SPIKE WAVE; SYNAPTIC TRANSMISSION; TOXICITY TESTING; UNSTEADINESS; VERTIGO;

ANTICONVULSANTS; EPILEPSY; HUMANS;

EID: 80051547306     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.05.025     Document Type: Review

References (178)

1. Chong D.J., Bazil C.W. Update on anticonvulsant drugs. Curr Neurol Neurosci Rep 2010, 10:308-318.
2. Brodie M.J., Bamagous G., Kwan P. Improved outcomes in newly diagnosed epilepsy. Epilepsia 2009, 50:411-412.
3. Callaghan B.C., Anand K., Hesdorffer D., Hauser W.A., French J.A. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007, 62:382-389.
4. Luciano A.L., Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007, 62:375-381.
5. Beyenburg S., Stavem K., Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010, 51:7-26.
6. Gazzolla D.M., Balcer L.J., French J.A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007, 48:1303-1307.
7. Berg A.T., Shinnar S., Levy S.R., Testa F.M. Status epilepticus in children with newly diagnosed epilepsy. Ann Neurol 1999, 45:618-623.
8. Geerts A., Arts W.F., Stroink H., et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood. Epilepsia 2010, 51:1189-1197.
9. Sillanpaa M., Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 2009, 132:989-998.
10. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med, in press.
11. Krymchantowski A.V., Bigal M.E. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother 2006, 6:283-289.
12. Dworkin R.H., O'Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85:S3-S14.
13. Epstein B.J. Improving blood pressure control rates by optimizing combination antihypertensive therapy. Expert Opin Pharmacother 2010, 11:2011-2026.
14. Thompson M.A., Aberg J.A., Cahn P., et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304:321-333.
15. Cheung M.C., Haynes A.E., Meyer R.M., Stevens A., Imrie K.R. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev 2007, 33:161-176.
16. Engstrom P.F. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 2008, 28:18-22S.
17. Meisler M.H., Kearney J.A. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005, 115:2010-2017.
18. Catterall W.A., Kalume F., Oakley J.C. NaV1.1 channels and epilepsy. J Physiol 2010, 588:1849-1859.
19. Ogiwara I., Miyamoto H., Morita N., et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007, 27:5903-5914.
20. Yu F.H., Mantegazza M., Westenbroek R.E., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006, 9:1142-1149.
21. Guerrini R., Dravet C., Genton P., Belmonte A., Kaminska A., Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998, 39:508-512.
22. Liao Y., Deprez L., Maljevic S., et al. Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. Brain 2010, 133:1403-1414.
23. Vacher H., Mohapatra D.P., Trimmer J.S. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev 2008, 88:1407-1447.
24. Maljevic S., Wuttke T.V., Seebohm G., Lerche H. KV7 channelopathies. Pfluegers Arch 2010, 460:277-288.
25. Zuberi S.M., Eunson L.H., Spauschus A., et al. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 1999, 122(Pt. 5):817-825.
26. Du W., Bautista J.F., Yang H., et al. Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet 2005, 37:733-738.
27. Bernard C., Anderson A., Becker A., Poolos N.P., Beck H., Johnston D. Acquired dendritic channelopathy in temporal lobe epilepsy. Science 2004, 305:532-535.
28. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
29. Kito M., Maehara M., Watanabe K. Antiepileptic drugs: calcium current interaction in cultured human neuroblastoma cells. Seizure 1994, 3:141-149.
30. Poolos N.P., Migliore M., Johnston D. Pharmacological upregulation of H-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci 2002, 5:767-774.
31. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001, 90:21-34.
32. Stephen L.J., Brodie M.J. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011, 25:89-107.
33. Rundfeldt C., Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000, 282:73-76.
34. Wuttke T.V., Seebohm G., Bail S., Maljevic S., Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005, 67:1009-1017.
35. Delmas P., Brown D.A. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 2005, 6:850-862.
36. Main M.J., Cryan J.E., Dupere J.R., Cox B., Clare J.J., Burbidge S.A. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000, 58:253-262.
37. Brodie M.J., Lerche H., Gil-Nagel A., et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010, 75:1817-1824.
38. French J.A., Abou-Khalil B.W., Leroy R. Randomized double-blind placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011, 76:1555-1563. on behalf of the RESTORE 1/Study 301 investigators.
39. Rogawski M.A., Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004, 5:553-564.
40. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988, 2:145-181.
41. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010, 9:68-82.
42. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., Wolf H.H. Discovery and preclinical development of antiepileptic drugs. Antiepileptic drugs 2002, 36-48. Lippincott Williams & Williams, Philadelphia. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
43. Stables J.P., Bertram E., Dudek F.E., et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES Models II Workshop. Epilepsia 2003, 44:1472-1478.
44. McNamara J.O. Development of new pharmacological agents for epilepsy: lessons from the kindling model. Epilepsia 1989, 30(Suppl. 1):S13-S18.
45. Sills G.J., Brodie M.J. Preclinical drug development in epilepsy. Encyclopedia of basic epilepsy research 2009, 97-103. Elsevier, London. P.A. Schwartzkroin (Ed.).
46. Kupferberg H.J., Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. Epilepsy: a comprehensive textbook 1997, 1417-1434. Lippincott-Raven, Philadelphia. J. Engel, T.A. Pedley (Eds.).
47. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007, 69:1751-1760.
48. Krauss G.L., Bergin A., Kramer R.E., Cho Y.W., Reich S.G. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001, 56:411-412.
49. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
50. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998, 39:5-17.
51. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
52. Glauser T.A., Cnaan A., Shinnar S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
53. Schmidt D., Holmes G.L. Commentary: novel delivery approaches for antiepileptic drugs: hope and hurdles. Neurotherapeutics 2009, 6:381-382.
54. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
55. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
56. Specchio L.M., Gambardella A., Giallonardo A.T., et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006, 71:32-39.
57. Glauser T., Kluger G., Sachdeo R., Krauss G., Perdomo C., Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
58. Elterman R.D., Shields W.D., Mansfield K.A., Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
59. Chiron C., Marchand M.C., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000, 356:1638-1642. for the STICLO Study Group.
60. Toledano R., Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol 2008, 28:317-327.
61. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
62. Besag F.M., Berry D.J., Pool F., Newbery J.E., Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998, 39:183-187.
63. Brodie M.J., Yuen A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate?. Epilepsy Res 1997, 26:423-432. for the 105 Study Group.
64. Saké J.-K., Herbert D., Isojarvi J., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
65. Holmes G.L., Frank L.M., Sheth R.D., et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008, 82:124-132.
66. Labiner D.M., Ettinger A.B., Fakhoury T.A., et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009, 50:434-442.
67. Arcas J., Ferrer T., Roche M.C., Martinez-Bermejo A., Lopez-Martin V. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001, 42:1363-1365.
68. Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004, 13(Suppl. 1):S50-S55.
69. Ohtahara S., Yamatogi Y. Erratum to "Safety of zonisamide therapy: prospective follow-up survey.". Seizure 2007, 16:87-93.
70. Sander J.W., Hart Y.M. Vigabatrin and behaviour disturbances. Lancet 1990, 335:57.
71. Marsh E.D., Brooks-Kayal A.R., Porter B.E. Seizures and antiepileptic drugs: does exposure alter normal brain development?. Epilepsia 2006, 47:1999-2010.
72. Cohen I., Navarro V., Clemenceau S., Baulac M., Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002, 298:1418-1421.
73. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993, 43:478-483. First Seizure Trial Group.
74. Leone M.A., Solari A., Beghi E. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology 2006, 67:2227-2229.
75. Musicco M., Beghi E., Solari A., Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997, 49:991-998. for the First Seizure Trial Group.
76. Schachter S.C., LaFrance W.C., eds Gates and Rowan's: Nonepileptic seizures 2010, Cambridge University Press, Cambridge. Third Edition.
77. Covanis A., Gupta A.K., Jeavons P.M. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982, 23:693-720.
78. Jentink J., Loane M.A., Dolk H., et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
79. Tomson T., Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009, 27:993-1002.
80. Banach R., Boskovic R., Einarson T., Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010, 33:73-79.
81. Bromley R.L., Mawer G., Love J., et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
82. Meador K.J., Baker G.A., Browning N., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
83. Chung A.M., Eiland L.S. Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs 2008, 10:217-254.
84. Crespel A., Genton P., Berramdane M., et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005, 65:762-764.
85. Sharpe D.V., Patel A.D., Abou-Khalil B., Fenichel G.M. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure 2008, 17:64-68.
86. Covanis A., Skiadas K., Loli N., Lada C., Theodorou V. Absence epilepsy: early prognostic signs. Seizure 1992, 1:281-289.
87. Rowan A.J., Meijer J.W., de Beer-Pawlikowski N., van der Geest P., Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983, 40:797-802.
88. Modur P.N., Milteer W.E. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav 2008, 13:554-556.
89. Sazgar M., Bourgeois B.F. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005, 33:227-234.
90. Kellinghaus C., Dziewas R., Ludemann P. Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure 2002, 11:243-249.
91. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40:985-991.
92. Kaminski R.M., Matagne A., Patsalos P.N., Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009, 50:387-397.
93. Kwan P., Brodie M.J. Combination therapy in epilepsy: when and what to use. Drugs 2006, 66:1817-1829.
94. Marescaux C., Hirsch E., Finck S., et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990, 31:768-777.
95. Fejerman N., Di Blasi A.M. Status epilepticus of benign partial epilepsies in children: report of two cases. Epilepsia 1987, 28:351-355.
96. Kikumoto K., Yoshinaga H., Oka M., et al. EEG and seizure exacerbation induced by carbamazepine in Panayiotopoulos syndrome. Epileptic Disord 2006, 8:53-56.
97. Bello-Espinosa L.E., Roberts S.L. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes: three cases. Seizure 2003, 12:157-159.
98. Coppola G., Franzoni E., Verrotti A., et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev 2007, 29:281-284.
99. Garcia C., Rubio G. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. Epilepsy Res 2009, 85:318-320.
100. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007, 9:353-412.
101. Bast T., Volp A., Wolf C., Rating D. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia 2003, 44:215-220.
102. Engler F., Maeder-Ingvar M., Roulet E., Deonna T. Treatment with sulthiame (Ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics 2003, 34:105-109.
103. Engel J. Report of the ILAE classification core group. Epilepsia 2006, 47:1558-1568.
104. Wohlrab G., Boltshauser E., Schmitt B. Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 1998, 29:133-136.
105. Escayg A., Goldin A.L. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010, 51:1650-1658.
106. Fisher J.L. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009, 56:190-197.
107. Grosso S., Franzoni E., Iannetti P., et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 2005, 20:893-897.
108. Wirrell E., Ho A.W., Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol 2006, 35:204-208.
109. Reife R. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. Antiepileptic drug development. Advances in Neurology 1998, 95-103. Lippincott-Raven, Philadelphia. J. French, I. Leppik, M.A. Dichter (Eds.).
110. Jonker D.M., Voskuyl R.A., Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?. Epilepsia 2007, 48:412-434.
111. Tallarida R.J. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006, 319:1-7.
112. Weaver L.C., Swinyard E.A., Woodbury L.A., Goodman L.S. Studies on anticonvulsant drug combinations: phenobarbital and diphenylhydantoin. J Pharmacol Exp Ther 1955, 113:359-370.
113. Deckers C.L., Czuczwar S.J., Hekster Y.A., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
114. Bourgeois B.F. Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiedebergs Arch Pharmacol 1986, 333:406-411.
115. Morris J.C., Dodson W.E., Hatlelid J.M., Ferrendelli J.A. Phenytoin and carbamazepine, alone and in combination: anticonvulsant and neurotoxic effects. Neurology 1987, 37:1111-1118.
116. Stafstrom C.E. Mechanisms of action of antiepileptic drugs: the search for synergy. Curr Opin Neurol 2010, 23:157-163.
117. Czuczwar S.J., Borowicz K.K. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002, 52:15-23.
118. Luszczki J.J., Czuczwar S.J. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004, 45:895-907.
119. Cuadrado A., de las Cuevas I., Valdizan E.M., Armijo J.A. Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. Eur J Pharmacol 2002, 453:43-52.
120. De Sarro G., Nava F., Aguglia U., De Sarro A. Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology 1996, 35:153-158.
121. Luszczki J.J., Czuczwar M., Kis J., et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003, 44:1003-1013.
122. Borowicz K.K., Swiader M., Luszczki J., Czuczwar S.J. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 2002, 43:956-963.
123. De Sarro G., Spagnolo C., Gareri P., Gallelli L., De Sarro A. Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur J Pharmacol 1998, 349:179-185.
124. Klitgaard H., Knudsen M.L., Jackson H.C. Synergism between drugs with different mechanisms of action against audiogenic seizures in DBA/2 mice. Epilepsia 1993, 34:93-94.
125. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347-356.
126. Gatti G., Bartoli A., Marchiselli R., et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993, 36:603-606.
127. Mattson R.H., Cramer J.A., Williamson P.D., Novelly R.A. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol 1978, 3:20-25.
128. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
129. Messenheimer J., Mullens E.L., Giorgi L., Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998, 18:281-296.
130. Obach R.S., Walsky R.L., Venkatakrishnan K., Houston J.B., Tremaine L.M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005, 78:582-592.
131. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
132. Pisani F., Oteri G., Russo M.F., Di Perri R., Perucca E., Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999, 40:1141-1146.
133. Cereghino J.J., Brock J.T., Van Meter J.C., Penry J.K., Smith L.D., White B.G. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975, 18:733-741.
134. Brodie M.J., Mumford J.P. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999, 34:199-205. for the 012 Study Group.
135. Leach J.P., Brodie M.J. Synergism with GABAergic drugs in refractory epilepsy. Lancet 1994, 343:1650.
136. Stephen L.J., Sills G.J., Brodie M.J. Lamotrigine and topiramate may be a useful combination. Lancet 1998, 351:958-959.
137. Sills G.J., Brodie M.J. Update on the mechanisms of action of antiepileptic drugs. Epileptic Disord 2001, 3:165-172.
138. Beydoun A., D'Souza J., Hebert D., Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009, 9:33-42.
139. Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
140. Elger C.E., Stefan H., Mann A., Narurkar M., Sun Y., Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010, 88:255-263.
141. Wong I.C., Mawer G.E., Sander J.W., Lhatoo S.D. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001, 42:1354-1358.
142. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
143. Kwan P., Brodie M.J. Definition of refractory epilepsy: defining the indefinable?. Lancet Neurol 2010, 9:27-29.
144. Stephen L.J., Brodie M.J. Seizure freedom with more than one antiepileptic drug. Seizure 2002, 11:349-351.
145. Brodie M.J., Kwan P. Staged approach to epilepsy management. Neurology 2002, 58:S2-S8.
146. Beghi E., Gatti G., Tonini C., et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003, 57:1-13.
147. Ettinger A.B., Argoff C.E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007, 4:75-83.
148. Spina E., Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004, 6:57-75.
149. Johannessen L.C., Johannessen S.I. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008, 68:1925-1939.
150. Rogawski M.A., Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004, 10:685-692.
151. Deckers C.L., Hekster Y.A., Keyser A., Meinardi H., Renier W.O. Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects. Epilepsia 1997, 38:570-575.
152. Canevini M.P., De S.G., Galimberti C.A., et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010, 51:797-804.
153. Devinsky O. Patients with refractory seizures. N Engl J Med 1999, 340:1565-1570.
154. Stables J.P., Bertram E.H., White H.S., et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 2002, 43:1410-1420.
155. Mantegazza M., Curia G., Biagini G., Ragsdale D.S., Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 2010, 9:413-424.
156. Remy S., Gabriel S., Urban B.W., et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003, 53:469-479.
157. Johnston G.A. GABA(A) receptor channel pharmacology. Curr Pharm Des 2005, 11:1867-1885.
158. Brooks-Kayal A.R., Shumate M.D., Jin H., Rikhter T.Y., Coulter D.A. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998, 4:1166-1172.
159. Langen B., Egerland U., Bernoster K., Dost R., Unverferth K., Rundfeldt C. Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J Pharmacol Exp Ther 2005, 314:717-724.
160. Stell B.M., Brickley S.G., Tang C.Y., Farrant M., Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. Proc Natl Acad Sci USA 2003, 100:14439-14444.
161. Madsen K.K., Clausen R.P., Larsson O.M., Krogsgaard-Larsen P., Schousboe A., White H.S. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem 2009, 109(Suppl. 1):139-144.
162. Wulff H., Castle N.A., Pardo L.A. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009, 8:982-1001.
163. Benarroch E.E. Potassium channels: brief overview and implications in epilepsy. Neurology 2009, 72:664-669.
164. Wickenden A.D., Roeloffs R., McNaughton-Smith G., Rigdon G.C. KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opin Ther Patents 2004, 14:457-469.
165. Wickenden A.D., Yu W., Zou A., Jegla T., Wagoner P.K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000, 58:591-600.
166. Meldrum B.S., Rogawski M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4:18-61.
167. Nemani V.M., Binder D.K. Emerging role of gap junctions in epilepsy. Histol Histopathol 2005, 20:253-259.
168. Timofeev I., Steriade M. Neocortical seizures: initiation, development and cessation. Neuroscience 2004, 123:299-336.
169. Nakase T., Naus C.C. Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta 2004, 1662:149-158.
170. Venance L., Rozov A., Blatow M., Burnashev N., Feldmeyer D., Monyer H. Connexin expression in electrically coupled postnatal rat brain neurons. Proc Natl Acad Sci USA 2000, 97:10260-10265.
171. Gareri P., Condorelli D., Belluardo N., et al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice). Neuropharmacology 2005, 49:551-563.
172. Nilsen K.E., Kelso A.R., Cock H.R. Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. Epilepsia 2006, 47:1169-1175.
173. Herrmann S., Stieber J., Ludwig A. Pathophysiology of HCN channels. Pfluegers Arch 2007, 454:517-522.
174. Ludwig A., Budde T., Stieber J., et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J 2003, 22:216-224.
175. Shah M.M., Anderson A.E., Leung V., Lin X., Johnston D. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron 2004, 44:495-508.
176. Arias R.L., Bowlby M.R. Pharmacological characterization of antiepileptic drugs and experimental analgesics on low magnesium-induced hyperexcitability in rat hippocampal slices. Brain Res 2005, 1047:233-244.
177. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
178. Walker M.C., White H.S., Sander J.W. Disease modification in partial epilepsy. Brain 2002, 125:1937-1950.